Restricted accessResearch articleFirst published online 2025-09
How Do Hepatocyte MicroRNAs Play a Role in Hepatitis C Virus Replication and Pathogenesis? Emerging Hypotheses and Strategies for MicroRNA Therapeutics and Drug Development
Hepatitis C virus (HCV) is a major global health burden affecting millions worldwide. A deeper understanding of and theories on the mechanisms of HCV replication and pathogenesis would bode well for diagnostics and therapeutics innovation. For example, HCV is known to modulate the host genes (e.g., human hepatocytes) for its efficient viral replication. These host genes are, therefore, among the major targets for treatment of HCV infection. We report here a systematic computational study that involved biocuration of published biomedical literature and data and subsequent network analyses to identify the potential microRNA-based therapeutics targeting HCV replication. We identified 539 HCV induced unidirectionally differential regulated miRNAs and assembled 115 genes that are positively/negatively associated with HCV replication. Furthermore, interaction networks by viral proteins were constructed to reveal the regulation of these microRNA (miRNA)-modulated genes. We found hsa-miR-191-5p and choline kinase alpha (CHKA) as a significant microRNA-gene pair with relevance in glycerophospholipid metabolism, as validated by microarray expression profiles with temporal datasets. Altogether, these results provide comprehensive outline of the emerging data and hypotheses on the complex interplay between HCV and the host cells in modulating cellular miRNAs for viral proliferation. Our findings pave the way for the hypotheses that the induction of hsa-miR-191-5p or its delivery into hepatocytes or the inhibition of CHKA activity could be a potential therapeutic strategy to combat HCV-associated pathologies in the future.
Get full access to this article
View all access options for this article.
References
1.
AntilN, ArefianM, KandiyilMK, et al.The core human MicroRNAs regulated by toxoplasma gondii. Microrna, 2022; 11(2):163–174; doi: 10.2174/2211536611666220428130250
2.
AriumiY, KurokiM, AbeK, et al.DDX3 DEAD-Box RNA helicase is required for hepatitis C virus RNA replication. J Virol, 2007; 81(24):13922–13926; doi: 10.1128/JVI.01517-07
3.
BairochA. The cellosaurus, a cell-line knowledge resource. J Biomol Tech, 2018; 29(2):25–38; doi: 10.7171/jbt.18-2902-002
4.
BanaudhaK, KaliszewskiM, KorolnekT, et al.MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology, 2011; 53(1):53–61; doi: 10.1002/hep.24016
5.
BartenschlagerR, FreseM, PietschmannT. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res, 2004; 63:71–180; doi: 10.1016/S0065-3527(04)63002-8
6.
BlackhamS, BaillieA, Al-HababiF, et al.Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus. J Virol, 2010; 84(10):5404–5414; doi: 10.1128/JVI.02529-09
7.
BrueningJ, WeigelB, GeroldG. The role of Type III interferons in hepatitis C virus infection and therapy. J Immunol Res, 2017; 2017:7232361; doi: 10.1155/2017/7232361
8.
CarbonS, IrelandA, MungallCJ, et al.; Web Presence Working Group. AmiGO: Online access to ontology and annotation data. Bioinformatics, 2009; 25(2):288–289; doi: 10.1093/bioinformatics/btn615
9.
CastelloG, ScalaS, PalmieriG, et al.HCV-Related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol, 2010; 134(3):237–250; doi: 10.1016/j.clim.2009.10.007
10.
CloughE, BarrettT, WilhiteSE, et al.NCBI GEO: Archive for gene expression and epigenomics data sets: 23-Year update. Nucleic Acids Res, 2024; 52(D1):D138–D144; doi: 10.1093/nar/gkad965
11.
ColpittsCC, TsaiP-L, ZeiselMB. Hepatitis C virus entry: An intriguingly complex and highly regulated process. Int J Mol Sci, 2020; 21(6):2091; doi: 10.3390/ijms21062091
12.
DattaN, JohnsonC, KaoD, et al.MicroRNA-Based therapeutics for inflammatory disorders of the microbiota-gut-brain axis. Pharmacol Res, 2023; 194:106870; doi: 10.1016/j.phrs.2023.106870
13.
DuponchelS, MonnierL, MolleJ, et al.Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes. JHEP Rep, 2023; 5(3):100647; doi: 10.1016/j.jhepr.2022.100647
FahmaA, SubairS, RamakrishnanK, et al.Exploring the shared MiRNA-MRNA signature network between helicobacter pylori infection and gastric cancer: A comparative study. Curr Microbiol, 2025; 82(8):366; doi: 10.1007/s00284-025-04336-5
16.
FraustoSD, LeeE, TangH. Cyclophilins as modulators of viral replication. Viruses, 2013; 5(7):1684–1701; doi: 10.3390/v5071684
17.
GawlikK, GallayPA. HCV core protein and virus assembly: What we know without structures. Immunol Res, 2014; 60(1):1–10; doi: 10.1007/s12026-014-8494-3
18.
GeSX, JungD, YaoR. ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinformatics, 2020; 36(8):2628–2629; doi: 10.1093/bioinformatics/btz931
19.
GebertLFR, RebhanMAE, CrivelliSEM, et al.Miravirsen (SPC3649) can inhibit the biogenesis of MiR-122. Nucleic Acids Res, 2014; 42(1):609–621; doi: 10.1093/nar/gkt852
GuS, JinL, ZhangF, et al.Biological basis for restriction of MicroRNA targets to the 3′ untranslated region in mammalian MRNAs. Nat Struct Mol Biol, 2009; 16(2):144–150; doi: 10.1038/nsmb.1552
22.
GuoX, ZhongJ-Y, LiJ-W. Hepatitis C virus infection and vaccine development. J Clin Exp Hepatol, 2018; 8(2):195–204; doi: 10.1016/j.jceh.2018.02.003
23.
HaddadJG, RouilleY, HanoulleX, et al.Identification of novel functions for hepatitis C virus envelope glycoprotein E1 in virus entry and assembly. J Virol, 2017; 91(8):e00048–e00017; doi: 10.1128/JVI.00048-17
24.
HelbigKJ, EyreNS, YipE, et al.The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. Hepatology, 2011; 54(5):1506–1517; doi: 10.1002/hep.24542
25.
HenkeJI, GoergenD, ZhengJ, et al.MicroRNA-122 stimulates translation of hepatitis C virus RNA. Embo J, 2008; 27(24):3300–3310; doi: 10.1038/emboj.2008.244
26.
HochbergY, BenjaminiY. More powerful procedures for multiple significance testing. Stat Med, 1990; 9(7):811–818; doi: 10.1002/sim.4780090710
27.
HouW, TianQ, ZhengJ, et al.MicroRNA-196 represses bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology, 2010; 51(5):1494–1504; doi: 10.1002/hep.23401
28.
HuangH-Y, LinY-C-D, CuiS, et al.MiRTarBase update 2022: An informative resource for experimentally validated MiRNA-Target interactions. Nucleic Acids Res, 2022; 50(D1):D222–D230; doi: 10.1093/nar/gkab1079
29.
HuangP-S, LiaoC-J, HuangY-H, et al.Functional and clinical significance of dysregulated MicroRNAs in liver cancer. Cancers (Basel), 2021; 13(21):5361; doi: 10.3390/cancers13215361
30.
IslamKU, AnwarS, PatelAA, et al.Global lipidome profiling revealed multifaceted role of lipid species in hepatitis C virus replication, assembly, and host antiviral response. Viruses, 2023; 15(2):464; doi: 10.3390/v15020464
31.
IzumidaK, MoritaE. The roles of HCV core protein and its binding host factor in virus assembly and release. Front Virol, 2024; 4; doi: 10.3389/fviro.2024.1383261
32.
JanssenHLA, ReesinkHW, LawitzEJ, et al.Treatment of HCV infection by targeting MicroRNA. N Engl J Med, 2013; 368(18):1685–1694; doi: 10.1056/NEJMoa1209026
33.
JoplingCL, SchützS, SarnowP. Position-Dependent function for a tandem MicroRNA MiR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe, 2008; 4(1):77–85; doi: 10.1016/j.chom.2008.05.013
34.
JoplingCL. Targeting MicroRNA-122 to treat hepatitis C virus infection. Viruses, 2010; 2(7):1382–1393; doi: 10.3390/v2071382
35.
KaragkouniD, ParaskevopoulouMD, ChatzopoulosS, et al.DIANA-TarBase v8: A decade-long collection of experimentally supported MiRNA-Gene interactions. Nucleic Acids Res, 2018; 46(D1):D239–D245; doi: 10.1093/nar/gkx1141
36.
KaulA, StaufferS, BergerC, et al.Essential role of cyclophilin a for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog, 2009; 5(8):e1000546; doi: 10.1371/journal.ppat.1000546
37.
KozomaraA, BirgaoanuM, Griffiths-JonesS. MiRBase: From MicroRNA sequences to function. Nucleic Acids Res, 2019; 47(D1):D155–D162; doi: 10.1093/nar/gky1141
38.
LavanchyD. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect, 2011; 17(2):107–115; doi: 10.1111/j.1469-0691.2010.03432.x
39.
LavanchyD. The global burden of hepatitis C. Liver Int, 2009; 29(Suppl 1):74–81; doi: 10.1111/j.1478-3231.2008.01934.x
40.
LeeCH, KimJH, LeeS-W. The role of MicroRNA in pathogenesis and as markers of HCV chronic infection. Curr Drug Targets, 2017; 18(7):756–765; doi: 10.2174/1389450117666160401125213
41.
LiH, HuangM-H, JiangJ-D, et al.Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy. World J Gastroenterol, 2018; 24(47):5297–5311; doi: 10.3748/wjg.v24.i47.5297
42.
LiH, JiangJ-D, PengZ-G. MicroRNA-Mediated interactions between host and hepatitis C virus. World J Gastroenterol, 2016; 22(4):1487–1496; doi: 10.3748/wjg.v22.i4.1487
LiangY, ZhangG, LiQ, et al.TRIM26 is a critical host factor for HCV replication and contributes to host tropism. Sci Adv, 2021; 7(2):eabd9732; doi: 10.1126/sciadv.abd9732
47.
LimanW, OubahmaneM, LahcenNA, et al.Computational design of potent dimeric phenylthiazole NS5A inhibitors for hepatitis C virus. Sci Rep, 2024; 14(1):31655; doi: 10.1038/s41598-024-80082-1
48.
LiuY, WimmerE, PaulAV. Cis-Acting RNA elements in human and animal plus-Strand RNA viruses. Biochim Biophys Acta, 2009; 1789(9–10):495–517; doi: 10.1016/j.bbagrm.2009.09.007
49.
LohmannV. Hepatitis C virus RNA replication. Curr Top Microbiol Immunol, 2013; 369:167–198; doi: 10.1007/978-3-642-27340-7_7
50.
LuoW, BrouwerC. Pathview: An R/Bioconductor package for pathway-based data integration and visualization. Bioinformatics, 2013; 29(14):1830–1831; doi: 10.1093/bioinformatics/btt285
51.
MacfarlaneL-A, MurphyPR. MicroRNA: Biogenesis, function and role in cancer. Curr Genomics, 2010; 11(7):537–561; doi: 10.2174/138920210793175895
52.
MachlinES, SarnowP, SaganSM. Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional MicroRNA-Target RNA complex. Proc Natl Acad Sci U S A, 2011; 108(8):3193–3198; doi: 10.1073/pnas.1012464108
53.
MacPhersonJI, SiddersB, WielandS, et al.An integrated transcriptomic and meta-analysis of hepatoma cells reveals factors that influence susceptibility to HCV infection. Kaushal D. ed. PLoS One, 2011; 6(10):e25584; doi: 10.1371/journal.pone.0025584
54.
MannsMP, ButiM, GaneE, et al.Hepatitis C virus infection. Nat Rev Dis Primers, 2017; 3:17006; doi: 10.1038/nrdp.2017.6
55.
MauriM, ElliT, CavigliaG, et al.RAWGraphs. In: Proceedings of the 12th Biannual Conference on Italian SIGCHI Chapter ACM: New York, NY, USA; 2017; pp. 1–5; doi: 10.1145/3125571.3125585
56.
McFarlandAP, HornerSM, JarretA, et al.The favorable IFNL3 genotype escapes MRNA decay mediated by AU-Rich elements and hepatitis C virus-induced MicroRNAs. Nat Immunol, 2014; 15(1):72–79; doi: 10.1038/ni.2758
57.
McMullanLK, GrakouiA, EvansMJ, et al.Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U S A, 2007; 104(8):2879–2884; doi: 10.1073/pnas.0611267104
58.
MegahedF, TabllA, AttaS, et al.MicroRNAs: Small molecules with significant functions, particularly in the context of viral hepatitis B and C infection. Medicina (Kaunas), 2023; 59(1):173; doi: 10.3390/medicina59010173
59.
MingoranceL, CastroV, Avila-PerezG, et al.Host phosphatidic acid phosphatase Lipin1 is rate limiting for functional hepatitis C virus replicase complex formation. PLoS Pathog, 2018; 14(9):e1007284; doi: 10.1371/journal.ppat.1007284
60.
MirzaeiR, KarampoorS, KorotkovaNL. The emerging role of MiRNA-122 in infectious diseases: Mechanisms and potential biomarkers. Pathol Res Pract, 2023; 249:154725; doi: 10.1016/j.prp.2023.154725
61.
MitchellJK, LemonSM, McGivernDR. How do persistent infections with hepatitis C virus cause liver cancer? Curr Opin Virol, 2015; 14:101–108; doi: 10.1016/j.coviro.2015.09.003
62.
MoradpourD, PeninF, RiceCM. Replication of hepatitis C virus. Nat Rev Microbiol, 2007; 5(6):453–463; doi: 10.1038/nrmicro1645
63.
MoradpourD, PeninF. Hepatitis C virus proteins: From structure to function. Curr Top Microbiol Immunol, 2013; 369:113–142; doi: 10.1007/978-3-642-27340-7_5
64.
NguyenDP, NguyenHX, Van NguyenH, et al.On the steroids extracted from soft corals against the NS3/4A protease of hepatitis C virus. J Mol Graph Model, 2025; 136:108936; doi: 10.1016/j.jmgm.2024.108936
PaulD, HoppeS, SaherG, et al.Morphological and biochemical characterization of the membranous hepatitis C virus replication compartment. J Virol, 2013; 87(19):10612–10627; doi: 10.1128/JVI.01370-13
67.
PengX, LiY, WaltersK-A, et al.Computational identification of hepatitis C virus associated MicroRNA-MRNA regulatory modules in human livers. BMC Genomics, 2009; 10(1):373; doi: 10.1186/1471-2164-10-373
68.
PowellBH, WitwerKW, MeffertMK. Cellular MiRNAs and viruses: Trends in MiRNA sequestering and target de-repression. J Virol, 2025; 99(7):e0091425; doi: 10.1128/jvi.00914-25
69.
RamakrishnanK, BabuS, ShajiV, et al.Hepatitis B virus modulated transcriptional regulatory map of hepatic cellular MicroRNAs. OMICS, 2023; 27(12):581–597; doi: 10.1089/omi.2023.0171
70.
RamakrishnanK, VishwakarmaR, DevRR, et al.Etiologically significant MicroRNAs in hepatitis B Virus-Induced hepatocellular carcinoma. OMICS, 2024; 28(6):280–290; doi: 10.1089/omi.2024.0071
71.
RameshP, BabuS, AmmankalluS, et al.Helicobacter pylori regulated MicroRNA map of human gastric cells. Helicobacter, 2023; 28(1):e12941; doi: 10.1111/hel.12941
72.
Ramirez de MolinaA, Gallego-OrtegaD, SarmenteroJ, et al.Choline kinase is a novel oncogene that potentiates RhoA-Induced carcinogenesis. Cancer Res, 2005; 65(13):5647–5653; doi: 10.1158/0008-5472.CAN-04-4416
73.
Ramirez de MolinaA, Rodriguez-GonzalezA, GutierrezR, et al.Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun, 2002; 296(3):580–583; doi: 10.1016/s0006-291x(02)00920-8
74.
ReissS, RebhanI, BackesP, et al.Recruitment and activation of a lipid kinase by hepatitis C Virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe, 2011; 9(1):32–45; doi: 10.1016/j.chom.2010.12.002
75.
RevikumarA, NairAS, SundaramSV. Structure based virtual screening of inhibitors for binding at the allosteric site of HCV RNA dependent RNA polymerase. Bioinformation, 2012; 8(15):716–719; doi: 10.6026/97320630008716
76.
ScottS, LiY, BermekO, et al.Binding of MicroRNA-122 to the hepatitis C virus 5′ untranslated region modifies interactions with poly(C) binding protein 2 and the NS5B viral polymerase. Nucleic Acids Res, 2023; 51(22):12397–12413; doi: 10.1093/nar/gkad1000
77.
ShannonP, MarkielA, OzierO, et al.Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13(11):2498–2504; doi: 10.1101/gr.1239303
78.
ShiST, LeeK-J, AizakiH, et al.Hepatitis C virus RNA replication occurs on a detergent-resistant membrane that cofractionates with Caveolin-2. J Virol, 2003; 77(7):4160–4168; doi: 10.1128/jvi.77.7.4160-4168.2003
79.
ShimakamiT, YamaneD, JangraRK, et al.Stabilization of hepatitis C virus RNA by an Ago2-MiR-122 complex. Proc Natl Acad Sci U S A, 2012a;109(3):941–946; doi: 10.1073/pnas.1112263109
80.
ShimakamiT, YamaneD, WelschC, et al.Base pairing between hepatitis C virus RNA and MicroRNA 122 3′ of its seed sequence is essential for genome stabilization and production of infectious virus. J Virol, 2012b;86(13):7372–7383; doi: 10.1128/JVI.00513-12
81.
ShrivastavaS, SteeleR, RayR, et al.MicroRNAs: Role in hepatitis C virus pathogenesis. Genes Dis, 2015; 2(1):35–45; doi: 10.1016/j.gendis.2015.01.001
82.
SmythGK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol, 2004; 3(1):1–25; doi: 10.2202/1544-6115.1027
83.
SunC, PagerCT, LuoG, et al.Hepatitis C virus core-derived peptides inhibit genotype 1b viral genome replication via interaction with DDX3X. PLoS One, 2010; 5(9):e12826; doi: 10.1371/journal.pone.0012826
84.
TakamizawaA, MoriC, FukeI, et al.Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol, 1991; 65(3):1105–1113; doi: 10.1128/JVI.65.3.1105-1113.1991
85.
TangW, TaoY, FajardoE, et al.Diagnostic accuracy of point-of-care HCV viral load assays for HCV diagnosis: A systematic review and meta-analysis. Diagnostics (Basel), 2022; 12(5):1255; doi: 10.3390/diagnostics12051255
86.
TellinghuisenTL, EvansMJ, von HahnT, et al.Studying hepatitis C Virus: Making the best of a bad virus. J Virol, 2007; 81(17):8853–8867; doi: 10.1128/JVI.00753-07
87.
ThibaultPA, WilsonJA. Targeting MiRNAs to treat hepatitis C virus infections and liver pathology: Inhibiting the virus and altering the host. Pharmacol Res, 2013; 75:48–59; doi: 10.1016/j.phrs.2013.03.004
88.
UraS, HondaM, YamashitaT, et al.Differential MicroRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology, 2009; 49(4):1098–1112; doi: 10.1002/hep.22749
89.
WongM-T, ChenSS. Hepatitis C virus subverts human choline Kinase-α To Bridge Phosphatidylinositol-4-Kinase IIIα (PI4KIIIα) and NS5A and upregulates PI4KIIIα activation, thereby promoting the translocation of the ternary complex to the endoplasmic reticulum for viral replication. J Virol, 2017; 91(16):10–1128; doi: 10.1128/JVI.00355-17
90.
WongM-T, ChenSS. Human choline Kinase-α promotes hepatitis C virus RNA replication through modulation of membranous viral replication complex formation. J Virol, 2016; 90(20):9075–9095; doi: 10.1128/JVI.00960-16
91.
WuQ, LiZ, MellorP, et al.The role of PTEN—HCV core interaction in hepatitis C virus replication. Sci Rep, 2017; 7(1):3695; doi: 10.1038/s41598-017-03052-w
92.
XieD-Y, WangS-M, YangJ-M, et al.IFIT1 polymorphisms predict Interferon-α treatment efficiency for hepatitis B virus infection. World J Gastroenterol, 2016; 22(44):9813–9821; doi: 10.3748/wjg.v22.i44.9813
93.
YangX, LianX, FuC, et al.HVIDB: A comprehensive database for human-virus protein-protein interactions. Brief Bioinform, 2021; 22(2):832–844; doi: 10.1093/bib/bbaa425
94.
ZaltronS, SpinettiA, BiasiL, et al.Chronic HCV infection: Epidemiological and clinical relevance. BMC Infect Dis, 2012; 12(Suppl 2):S2; doi: 10.1186/1471-2334-12-S2-S2
95.
ZeremskiM, PetrovicLM, TalalAH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat, 2007; 14(10):675–687; doi: 10.1111/j.1365-2893.2006.00838.x
96.
ZhangY, LiR-Q, FengX-D, et al.Down-Regulation of PTEN by HCV core protein through activating nuclear Factor-ΚB. Int J Clin Exp Pathol, 2014; 7(11):7351–7359.
